1.75-Dose New Drug Achieves 100% Remission in Lymphoma
On December 8, Merck announced the preliminary results of its Phase II waveLINE-007 study for the first time. This study aimed to evaluate the efficacy and safety of the antibody-drug conjugate (ADC) zilovertamab vedotin, targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment-naive patients with diffuse large B-cell lymphoma (DLBCL). The results showed that in the patient group receiving a dose of 1.75 mg/kg of zilovertamab vedotin (n=15), the complete remission rate (CR) reached 100%. These data were presented in an oral report at the 66th Annual Meeting of the American Society of Hematology (ASH) and were assigned abstract number #578.
Merck acquired VelosBio for $2.75 billion in November 2020, gaining its ROR1 ADC drug, zilovertamab vedotin (VLS-101), which was then in early clinical development and had received orphan drug designation (ODD) and fast track designation (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma (MCL).
The waveLINE-007 study is an open-label Phase II clinical trial (NCT05406401) that enrolled 36 treatment-naive DLBCL patients, divided into three treatment groups based on the dosage of zilovertamab vedotin (1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg). The primary endpoints were safety assessment and complete remission rate (CR), with secondary endpoints including objective response rate (ORR) and duration of remission (DOR).
Efficacy results indicated that the complete remission rates for the three different dosage groups of zilovertamab vedotin were 100% (n=15), 93.3% (n=14), and 100% (n=6), leading to an overall complete remission rate of 97.2%. However, one patient in each of the 2.0 mg/kg and 2.25 mg/kg dosage groups discontinued treatment due to adverse events, confirming the optimal dosage as 1.75 mg/kg.
Regarding safety, the incidence of serious treatment-related adverse events (TRAE) was 11% (n=4), while the incidence of grade 3-4 TRAEs was 58% (n=21). The most common adverse events included neutropenia, nausea, anemia, and diarrhea.
Dr. Muhit Ozcan, the principal investigator from Ankara University Medical School, noted, “Despite initial treatment, about 40% of DLBCL patients still experience poor efficacy or disease relapse, highlighting the urgent need for additional first-line treatment options for these patients. The data from the waveLINE-007 study is very promising and supports further clinical studies in larger patient populations to address unmet clinical needs.”
Dr. Gregory Lubiniecki, Vice President of Oncology Clinical Research at Merck Research Laboratories, expressed, “We are very pleased with the early positive results from the Phase II waveLINE-007 study, especially with the high response rate and manageable safety profile of zilovertamab vedotin when used in combination with standard therapies. We look forward to advancing research on ADC drugs targeting ROR1, believing it holds great potential in various hematological malignancies.”
2026-10-23
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
South Korea Approves Yeosu Restructuring Plan, Permanently Retiring 1.39 Million Tons of Ethylene Capacity
-
Sika in China Under Pressure: The Structural Alarm Behind the 1,500-Job Cut
-
Blue from the Rainforest: EFSA Greenlights Natural “Jagua Blue” as Safe Food Colorant
-
From Eggshell to Elixir: EFSA Declares Egg Membrane Collagen Peptides Safe for Adult Supplements
-
Probiotic Promise, Safety Snag: EFSA Gives Mixed Verdict on Multi-Strain Dog Feed Additive
-
From Ancient Volcanoes to Modern Feed Mills: EFSA Validates Volcanic Zeolite as Safe and Effective Feed Additive
-
Spice Up the Coop: EFSA Reaffirms Safety of Botanical Blend for Broiler Feed—With a Warning for Handlers
-
New Ocean Freight GRI Takes Effect on Asia, Middle East and Africa Routes to U.S. and Canada
-
Sun-Kissed Insect Oil? EFSA Approves UV-Treated Mealworm Fat as Safe—and Vitamin D-Rich—Novel Food
-
From Fungus to Food: EFSA Greenlights Rhizomucor pusillus Biomass as Safe Novel Ingredient
Recommend Reading
-
Butadiene Rubber's Cost in China Floor Collapses, Exports Hold the Line
-
Middle East Conflict Hits the Electronics Supply Chain as PPE Resin Shortage Sends PCB Prices Up 40%
-
UAE Withdraws from OPEC
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Business Society’s August 19, 2026 View on Isopropyl Alcohol Prices: Rising
-
Business Society’s Market Outlook for Acrylic Acid on August 19, 2026: Weak Rebound
-
In April, the natural rubber market in China showed a slight increase
-
Business Society’s Ethanol Market Outlook on August 18, 2026: Slightly Bearish Fluctuations
-
Business Society’s BDO Market Outlook on August 18, 2026: Clearly Upward
- Hot Searches
- where can i buy sulfur hexafluoride
- propylene glycol prices
- ammonium sulfide
- semaglutide research peptide for sale
- buy masteron
- where to buy reta peptide
- sds calcium carbide
- acrylonitrile.
- ammonia price index
- cost of calcitonin nasal spray
- reta peptides where to buy
- phosphorus pentoxide sds